Dr. Vonderheide, MD, DPhil, is is a distinguished laboratory scientist, clinician, and cancer leader who has deciphered mechanisms of cancer immune surveillance and developed novel cancer immunotherapies such as CD40 agonists with a particular focus on pancreatic cancer. He is a member of the NCI Board of Scientific Advisers, and the AACI and NCCN boards of directors. Funded by the NCI, SU2C-Lustgarten Foundation, and the Parker Institute, Dr. Vonderheide has published senior author manuscripts in Nature, Science, and the New England Journal of Medicine. Dr. Vonderheide has a long-standing commitment to AACR and is chair of the Program Committee for the 2023 AACR Annual Meeting.